Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 8/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.45 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.43 |
| ▸ | CTSV | O60911 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21617158 | 0.93 | CHRM4 (0.43) | CHRM4BRD4NR1H4 | |
| SCHEMBL21617281 | 0.90 | GPR132 (0.52) | CHRM4 | |
| SCHEMBL21617246 | 0.88 | BRD4 (0.40) | CHRM4BRD4 | |
| SCHEMBL31504340 | 0.88 | BRD4 (0.40) | CHRM4BRD4 | |
| SCHEMBL31504358 | 0.88 | HPGD (0.40) | CHRM4BRD4RAB9A | |
| SCHEMBL21617185 | 0.88 | HPGD (0.40) | CHRM4BRD4RAB9A | |
| SCHEMBL31504379 | 0.87 | CHRM4 (0.50) | CHRM4BRD4NR1H4SPHK2CTSV | |
| SCHEMBL21617216 | 0.87 | CHRM4 (0.50) | CHRM4BRD4NR1H4SPHK2CTSV | |
| SCHEMBL21617200 | 0.86 | CHRM4 (0.56) | CHRM4BRD4NR1H4NPC1RAB9A | |
| SCHEMBL31504432 | 0.86 | CHRM4 (0.56) | CHRM4BRD4NR1H4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3820850-B1 | PHENYL/PYRIDYL-N-PHENYL/PYRIDYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2026-04-01 | — | — | EP | disclosed |
| US-12421206-B2 | Aryl-n-aryl derivatives for treating a RNA virus infection | ABIVAX (FR) | 2025-09-23 | — | — | US | disclosed |
| CN-112638877-B | Phenyl/pyridinyl-N-phenyl/pyridinyl derivatives for the treatment of RNA viral infections | ABIVAX公司 | 2025-04-22 | — | — | CN | disclosed |
| EP-3820850-A1 | PHENYL/PYRIDYL-N-PHENYL/PYRIDYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2021-05-19 | — | — | EP | disclosed |
| US-20210122732-A1 | ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2021-04-29 | — | — | US | disclosed |
| US-20210122732-A1 | ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2021-04-29 | — | — | US | disclosed |
| WO-2020011816-A1 | PHENYL/PYRIDYL-N-PHENYL/PYRIDYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2020-01-16 | — | — | WO | disclosed |
| WO-2020011816-A1 | PHENYL/PYRIDYL-N-PHENYL/PYRIDYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2020-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421206-B2 | Aryl-n-aryl derivatives for treating a RNA virus infection | NSUN3, CBR3, C1R | CHRM4 1202/4885BRD4 1187/4885NR1H4 566/4885 |
| US-20210122732-A1 | ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | NSUN3, CBR3, C1R | CHRM4 1202/4885BRD4 1187/4885NR1H4 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.